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ABSTRACT
Aims/Introduction: The aim of the present study was to evaluate the properties of
the glucagon stimulation test (GST) and the normal meal tolerance test (NMTT) in patients
with type 2 diabetes.
Materials and Methods: We enrolled 142 patients with type 2 diabetes, and carried
out a GST and a NMTT. We carried out the NMTT using a calorie-controlled meal based
on an intake of 30 kcal/kg ideal bodyweight/day. We calculated the change in C-peptide
immunoreactivity (DCPR) by subtracting fasting CPR from the CPR 6 min after the 1-mg
glucagon injection (GST) or 120 min after the meal (NMTT).
Results: Mean DCPR for the GST was 2.0 ng/mL, and for the NMTT was 3.1 ng/mL. A
total of 104 patients had greater DCPR in the NMTT than the GST, and the mean DCPR
was significantly greater in the NMTT than the GST (P < 0.05). To exclude any influence of
antidiabetic drugs, we examined 42 individuals not taking antidiabetic agents, and found
the mean DCPR was significantly greater in the NMTT than the GST (GST 2.4 ng/mL,
NMTT 4.3 ng/mL; P < 0.05). To consider the influence of glucose toxicity, we carried out
receiver operating characteristic analyses with fasting plasma glucose and glycated hemo-
globin. The optimal cut-off levels predicting GST DCPR to be larger than NMTT DCPR
were fasting plasma glucose 147 mg/dL and glycated hemoglobin 9.0% (fasting plasma
glucose: sensitivity 0.64, specificity 0.76, area under the curve 0.73; glycated hemoglobin:
sensitivity 0.56, specificity 0.71, area under the curve 0.66).
Conclusions: The NMTT is a reliable insulin secretion test in patients with type 2
diabetes, except for those in a hyperglycemic state.
INTRODUCTION
Type 2 diabetes is a heterogeneous disease characterized by
insulin resistance and defective insulin secretion1. The
Prospective UK Diabetes Study Group reported that at the
time of diabetes diagnosis, b-cell function is reduced by up
to 50%, and deteriorates further regardless of therapy2. The
glucagon stimulation test (GST) is the current standard mea-
sure of endogenous insulin secretion. However, the GST has
adverse effects on patients and takes effort to administer3.
The mixed meal tolerance test (MMTT) as an assessment of
b-cell function is regarded as a more physiological test than
the GST, because it evaluates typical pancreatic postprandial
exposure to glucose and other nutrients, and gut and vagal
hormones4. However, in a hyperglycemic state, meal toler-
ance tests (MTTs) are more affected by glucotoxicity thanReceived 12 February 2017; revised 22 April 2017; accepted 1 May 2017
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the GST. This can be a problem, because for the MMTT,
patients are instructed to withhold their usual morning insu-
lin and oral hypoglycemic agents, and ingest a standardized
high-carbohydrate liquid mixed meal, which causes hyper-
glycemia5. We propose that to evaluate insulin secretion in a
real-world setting, a MTT is preferable to the GST provided
there is no hyperglycemia and the MTT is carried out under
everyday conditions (normal meal, continued use of medica-
tions). Therefore, we carried out a normal meal tolerance test
(NMTT) using a normal (calorie-controlled) meal with con-
tinued use of oral hypoglycemic agents and insulin treat-
ments, to use for comparison with the GST. We also
determined the fasting plasma glucose (FPG) and glycated
hemoglobin (HbA1c) levels indicative of hyperglycemia, above
which the GST is more reliable. The aim of the present
study was to carry out an evaluation of the NMMT and the
GST in patients with type 2 diabetes.
METHODS
The present study was cross-sectional and retrospective, and
complied with the recommendations of the Declaration of Hel-
sinki. The study was approved by the privacy policy committee
of the Tottori University Hospital.
Participants
A total of 142 inpatients with type 2 diabetes participated in
this study at Tottori University Hospital, Yonago, Tottori,
Japan, from 2011 to 2013. Type 2 diabetes mellitus was
diagnosed based on the criteria of the American Diabetes
Association6. Patients with pancreatic disease; liver disease;
pregnant; those taking diabetogenic medications, such as cor-
ticosteroids; or renal failure (serum creatinine >1.3 mg/dL)
were excluded from the present study. Clinical characteristics
of the participants are summarized in Table 1. Participants
included 87 men and 55 women with an average age of
62 years, HbA1c of 9.4%, body mass index of 24.7 kg/m2
and duration of diabetes of 11 years. Obesity (body mass
index >30 kg/m2) was present in 18 participants, while 55
were overweight (body mass index >25 kg/m2). Diabetic
retinopathy affected 56 participants, and diabetic nephropathy
affected 51 participants. Participants were receiving the fol-
lowing treatments at the time of study: diet therapy alone
(42 participants), oral hypoglycemic agents (OHAs) only (52
participants), insulin only (32 participants), and combined
OHA and insulin (16 participants). Participants were taking
the following medications: OHA (68 participants), sulfony-
lurea (44 participants), glinide (2 participants), biguanide (14
participants), alpha-glucosidase inhibitors (14 participants),
thiazolidine (3 participants) and dipeptidyl peptidase 4 inhibi-
tors (42 participants). A total of 48 participants were treated
with insulin, 36 with bolus insulin, 40 with basal insulin and
two with mixed insulin. To exclude the influence of antidia-
betic drugs, we examined 42 participants that were not tak-
ing antidiabetic agents.
Study design
We carried out the GST after an overnight fast using an intra-
venous injection of 1 mg glucagon. C-peptide immunoreactivity
(CPR) was measured at fasting before the glucagon injection
(GST FCPR) and 6 min after (GST CPR-6 min) the injection7.
The change in CPR was calculated by subtracting GST FCPR
from GST CPR-6 min (GST DCPR). The NMTT was carried
out at 08.00 hours after an overnight fast. Patients ingested a
calorie-controlled breakfast prescribed as nutritional therapy
according to the treatment guide for diabetes of the Japan Dia-
betes Society (total daily calorie intake 30 kcal/kg ideal body-
weight, single meal 25–33% of daily calorie intake with 60% of
calories as carbohydrates, 20% as lipids and 20% as protein)8,9.
For the NMTT, participants continued to take their usual
OHA and insulin treatments. CPR was measured at fasting
before the meal (NMTT FCPR) and 120 min after the meal
(NMTT CPR-120 min). The change in CPR was calculated by
subtracting NMTT FCPR from NMTT CPR-120 min (NMTT
DCPR).
Plasma glucose was measured using the glucose oxidase
method. Plasma insulin and CPR levels were measured using
chemiluminescent immunoassays (human insulin and CPR
chemiluminescent immunoassays kits; Kyowa Medix, Tokyo,
Japan). Plasma insulin was defined as immunoreactive insulin.
HbA1c was measured by high-performance liquid chromatogra-
phy, and converted to National Glycohemoglobin Standardiza-
tion Program values using the following equation: National
Glycohemoglobin Standardization Program (%) = 1.02 9 Japan
Diabetes Society (%) + 0.25%10.
Statistical analysis
Data are presented as mean – SEM. Differences in mean values
were determined using unpaired t-tests, and considered statisti-
cally significant at P < 0.05. In the hyperglycemic state, the
MTT DCPR is more affected by glucotoxicity than the GST
DCPR. Therefore, we determined cut-off values with a receiver
Table 1 | Clinical characteristics of the study participants
n 142
Sex (male/female) 80/62
Age (years) 61.5 – 14.0
BMI (kg/m2) 24.7 – 4.5
Duration of diabetes mellitus (years) 11.0 – 9.5
HbA1c, % (NGSP) 9.4 – 2.0





OHA + insulin 16
BMI, body mass index; HbA1c, glycated hemoglobin; NGSP, National
Glycohemoglobin Standardization Program; OHA, oral hypoglycemic
agents.
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operating characteristic (ROC) analysis of FPG and HbA1c.
The sensitivity of the FPG and HbA1c cut-off points was
defined as the ability of FPG or HbA1c to identify the GST
DCPR as larger than the NMTT DCPR. The specificity was
defined as the ability of FPG or HbA1c to identify the GST
DCPR as smaller than the NMTT DCPR. To evaluate the abili-
ties of FPG and HbA1c to detect the reactivity of DCPR, we
plotted ROC curves. Diagnostic properties of the cut-off levels
of FPG and HbA1c were defined by maximizing the sensitivity
and specificity to identify the GST DCPR as larger than the
NMTT DCPR. A ROC curve is a graph of sensitivity vs (1-spe-
cificity) for various cut-off definitions of a positive diagnostic
test result. The optimal cut-off points were obtained using the
Youden Index (maximum [sensitivity + specificity-1]), and
the point on the ROC curve closest to (0,1) was calculated as
the minimum value of the square root of ([1-sensitivity]2 + [1-
specificity]2)11,12. Greater accuracy is reflected by a larger You-
den Index and a smaller distance to (0, 1). SPSS 15.0 software
(SPSS, Chicago, Illinois, USA) was used for analysis.
RESULTS
For the GST, the mean plasma glucose at fasting and 6 min
after glucagon injection was 146 – 38 and 161 – 37 mg/dL,
respectively. The mean GST FCPR and the GST CPR-6 min
were 2.1 – 1.1 and 4.1 – 2.1 ng/mL, respectively, and the mean
GST DCPR was 2.0 – 1.3 ng/mL. For the NMTT, the mean
plasma glucose at fasting and 120 min post-meal was 154 – 45
and 255 – 66 mg/dL, respectively. The mean NMTT FCPR
and NMTT CPR-120 min were 2.1 – 1.1 and 5.3 – 2.6 ng/mL,
respectively, and the mean NMTT DCPR was 3.1 – 1.9 ng/mL
(Table 2). Of the 142 participants, 104 showed a greater DCPR
in the NMTT than the GST, and the mean NMTT DCPR was
significantly greater than the mean GST DCPR (P < 0.05; Fig-
ure 1). To exclude any influence of antidiabetic drugs, we
examined 42 participants that were not using antidiabetic
agents. The clinical characteristics of these participants are sum-
marized in Table 3. For participants not using antidiabetic
drugs, the mean GST DCPR was 2.4 ng/mL and the mean
NMTT DCPR was 4.3 ng/mL, and NMTT DCPR was signifi-
cantly greater than GST DCPR (P < 0.05; Table 4).
To consider the influence of glucose toxicity, we carried out
ROC analyses with FPG and HbA1c. The optimal cut-off levels
of FPG and HbA1c to identify the GST DCPR as larger than
the NMTT DCPR were 147 mg/dL and 9.0%, respectively. In
FPG 147 mg/dL, sensitivity was 0.64 and specificity was 0.76,
and area under ROC curve (AUC) was 0.73, representing mod-
erate accuracy. Similarly, in HbA1c 9.0%, sensitivity was 0.56
and specificity was 0.71, and AUC was 0.66, representing low
accuracy (Figure 2).
DISCUSSION
In the present study, the NMTT DCPR was greater than the
GST DCPR. This result agrees with a previous study on
patients with type 1 diabetes that found the MMTT to be supe-
rior to the GST when carried out under standardized condi-
tions3. This is probably because the MMTT causes an incretin
Table 2 | Results of glucagon stimulation test and the normal meal
tolerance test
GST NMTT P
Fasting PG (mg/dL) 146 – 38 154 – 45 <0.05
After load PG (mg/dL) 161 – 37 255 – 66 <0.05
Fasting CPR (ng/mL) 2.1 – 1.1 2.1 – 1.1 0.11
After load CPR (ng/mL) 4.1 – 2.1 5.3 – 2.6 <0.05
DCPR (mg/dL) 2.0 – 1.3 3.1 – 1.9 <0.05
Data represent mean – SD. After load, 6 min after glucagon injection
in the glucagon stimulation test or 120 min after a meal in the normal
meal tolerance test; CPR, C-peptide immunoreactivity; GST, glucagon




















Figure 1 | Results of C-peptide immunoreactivity (CPR) 6 min after
glucagon injection - fasting CPR (GSTDCPR) and CPR from CPR
120 min after meal - fasting CPR (NMTTDCPR). The line on the graph
expresses y = x. As for the participant above the line, NMTTDCPR is
higher than GSTDCPR.




Age (years) 61.8 – 14.1
BMI (kg/m2) 24.7 – 4.5
Duration of diabetes mellitus (years) 6.6 – 7.8
HbA1c, % (NGSP) 8.7 – 1.7
Fasting plasma glucose (mg/dL) 146 – 34
Data represent mean – SD. BMI, body mass index; HbA1c, glycated
hemoglobin; NGSP, National Glycohemoglobin Standardization Pro-
gram.
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effect whereby the oral glucose stimulus elicits greater insulin
secretion than a similar intravenous stimulus, through gastric
inhibitory polypeptide and glucagon-like peptide 1. The MMTT
is thus the gold standard measure of endogenous insulin
secretion for patients with type 1 or type 2 diabetes4. However,
while the full MMTT is used in research, it is rarely carried out
in routine clinical practice because of the intensity of sampling
required (samples are required every 30 min for 2 h to allow
measurement of AUC and peak CPR)13. Furthermore, the
MMTT has several problems as follows. First, the mixed meal
is liquid and composition is different from the normal food, so
the stimulation of insulin secretion might be different from the
normal food. Second, fixed-calorie test meals provide weak
stimulation for taller patients and strong stimulation for shorter
patients. Instead, we propose that calorie-controlled meals
would be preferable to fixed-calorie test meals for assessment of
insulin secretion ability in a real-world setting. Here, we carried
out a NMTT using calorie-controlled meals adjusted for ideal
bodyweight, and measured CPR just twice: at fasting and 2 h
after the meal. This NMTT is simple, making it more practical
for use in a clinical setting than the full MMTT or the GST.
In the chronic hyperglycemia state, glucose toxicity deterio-
rates meal-induced insulin secretion14. Funakoshi et al.15
reported that chronic high blood glucose shown by high
HbA1c levels might impair endogenous insulin secretion after a
meal load, but has little effect on endogenous insulin secretion
after a glucagon load. We also found that the NMTT DCPR
was more affected by glucose toxicity than the GST DCPR.
Therefore, we carried out ROC analyses to determine the cut-
off values of FPG and HbA1c. The cut-off values of FPG and
HbA1c at which GST DCPR was larger than NMTT DCPR
were 147 mg/dL and 9.0%, respectively. Thus, in the hyper-
glycemic state, especially when FPG is 147 mg/dL and HbA1c
is ≥9.0%, the NMTT DCPR might be an underestimate, and
GST should instead be carried out to assess endogenous insulin
secretion.
The present study had several limitations. First, the sample
size of the study was small, and we did not measure incretins.
We propose that the MTT DCPR was larger than the GST
DCPR because of the incretin effect, and that the incretin
effects were diminished in the hyperglycemic state. We hope to
measure incretins in future larger studies. Second, to assess
insulin secretion ability in a real-world setting and reduce the
hyperglycemia caused by the MTT, we continued the
Table 4 | Results of the glucagon stimulation test and normal meal
tolerance test in participants not using antidiabetic drugs
GST NMTT P
Fasting PG (mg/dL) 141 – 31 146 – 34 0.06
After load PG (mg/dL) 157 – 32 247 – 61 <0.05
Fasting CPR (ng/mL) 2.3 – 0.9 2.3 – 0.9 0.43
After load CPR (ng/mL) 4.7 – 2.0 6.6 – 2.4 <0.05
DCPR (mg/dL) 2.4 – 1.3 4.3 – 1.8 <0.05
Data represent mean – SD. After load, 6 min after glucagon injection
in the glucagon stimulation test or 120 min after a meal in the normal
meal tolerance test; CPR, C-peptide immunoreactivity; PG, plasma glu-






































Figure 2 | Change in C-peptide immunoreactivity (DCPR) during the
(a) glucagon stimulation test (GST) and (b) normal meal tolerance test
(NMTT). Receiver operating characteristic curves for change in C-peptide
immunoreactivity (DCPR) used to predict the cut-off points when DCPR
of the glucagon stimulation test (GST) is larger than that of the normal
meal tolerance test (NMTT). Sensitivity is plotted as a function of (1-
specificity). Points on the curve representing optimal fasting plasma
glucose (FPG) and glycated hemoglobin (HbA1c) are marked with an
arrow.
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participants’ use of their antidiabetic drugs, including OHAs
and insulin treatment. Sulfonylurea, glinide and dipeptidyl pep-
tidase 4 inhibitors encourage insulin secretion, so might have
affected CPR response in the MTT. A prior study of patients
with type 1 or type 2 diabetes receiving insulin treatment
showed that there was a 20% reduction in peak CPR value dur-
ing a MMTT when bolus insulin was given compared with no
bolus insulin given16. Another study reported that reducing
chronic hyperglycemia by basal insulin therapy enhanced
endogenous b-cell function after a MMTT17. These reports sug-
gest that insulin therapy affected CPR response in the MTT.
However, in the present study, the same results were obtained
from participants not using OHAs or insulin treatment, as
from all participants. Therefore, we propose that the NMTT is
useful in evaluating endogenous insulin secretion ability even
for patients taking antidiabetic medications. Giving antidiabetic
drugs to patients undergoing the NMTT makes little difference
to its ability to detect endogenous insulin secretion. Third, we
assessed fasting and 2-h CPR during the NMTT. Greenbaum
et al.3 reported that in the MMTT, CPR usually peaks around
90 min in patients with type 1 diabetes, and 90 min CPR has
been shown to be related to improved clinical outcomes18.
However, in the present study, we aimed to identify a method
for assessing insulin secretion ability that is easy to use during
daily clinical work. We assess postprandial plasma glucose at
2 h in daily clinical work, so chose to assess postprandial CPR
at the same time to streamline sampling efforts.
In conclusion, the NMTT is valuable as an insulin secretion
test in patients with type 2 diabetes, except under conditions of
hyperglycemia. In the hyperglycemic state, especially where
FPG is 147 mg/dL or HbA1c is ≥9.0%, the GST should be used
instead. Thus, the question of whether to use the GST or the
NMTT for measurement of insulin secretion can be answered
using levels of FPG or HbA1c.
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